VERU: Veru Pharma Price to Sales

Brandmark of Veru Inc (VERU)

Veru Inc. relies on high scalability upon FDA approval, where low capsule production costs combine with monopoly pricing. The company's average P/S confirms the market valuation, where 4.90 reflects the latest metric value. The process is accelerating through AI drug modeling, while the implementation of software robots for clinical test data analysis optimizes the time-to-market for medications.

VERU: Veru Inc. Market Cap to Revenue 07/04/2022 - 12/18/2025

Analytical breakdowns for Veru Pharma (VERU)

- current price and projected stock value:
Price Chart verupharma.com|VERU - Analyst Consensus Forecast
- market capitalization information:
Market Value Veru Pharma|VERU - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share Veru|VERU - Company Net Assets|Market Capitalization to Book Value Ratio verupharma.com|VERU - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Veru Inc.|VERU - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Veru Corporation|VERU - Company Debts|Debt to Book Value Ratio Veru Pharma|VERU - Company Long-Term Debts|Company Current Liabilities Veru|Interim Coverage Ratio verupharma.com
- earnings and valuation multiples information:
VERU - Net Income|Expected Profit Veru Inc.|VERU - P/E Multiple|Projected Price to Earnings Ratio Veru Inc|VERU - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Veru Pharma|VERU - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Veru|VERU - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months verupharma.com|VERU - Earnings growth in current year|Earnings growth forecast for next year Veru Inc.
- sales revenue and business income indicators:
VERU - Company Revenue|Company Revenue Forecast verupharma.com|VERU - P/S Multiple|Forward Price-to-Revenue Multiple Veru Pharma
Fundamental company analysis:verupharma.com (VERU)
Finished products of Veru Inc.

Veru Inc. development of oncology urology drugs and its close ties with clinics are reflected in the current P/S ratio dynamics. This metric compares market capitalization with annual sales volume to determine the cost of one dollar of revenue. The price-to-earnings ratio reveals the degree of asset overvaluation. Analyzing this coefficient allows an investor to assess the fairness of the pharmaceutical ecosystem's market value.

Competing companies

Price-to-Revenue Ratio ONC (beigene.com)|P/S Multiple HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Price to Sales|AAPG - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio CGON (CG Oncology Therapeutics)|URGN (UroGen Pharma Ltd.) - Market Cap to Revenue|bicara.com (BCAX) - P/S Multiple|Market Cap to Revenue PSNL|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|Price-to-Revenue Coefficient Y-mAbs Corp|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|CADL: Market Cap to Revenue Ratio|Accuray - P/S Multiple|SELLAS Life Sciences (SLS) - Market Cap to Revenue|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|CTOR - Price-to-Revenue Coefficient|Market Cap to Revenue HURA|Price-to-Revenue Ratio TARA|P/S Multiple FATE|WHWK - Price to Sales|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|Market Capitalization-to-Revenue Ratio CSBR|XBIT: Market Cap to Revenue|CVM - P/S Multiple|OSTX: P/S Multiple|Market Cap to Revenue radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|P/S Multiple Adlai Nortye Limited|Price-to-Revenue Ratio Tempest Therapeutics (TPST)|xiliotx.com - Market Cap to Revenue Ratio|P/S Multiple RENB (Renovaro)|MURA - Market Cap to Revenue|Kairos Pharma Inc - P/S Multiple|Price to Sales OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Price-to-Revenue Ratio|Curis - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue APLM|THAR: Market Capitalization-to-Revenue Ratio|P/S Multiple ADVB|Market Cap to Revenue Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Market Cap to Revenue|P/S Multiple sunshinebiopharma.com SBFM|XBIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SLRX (Salarius Pharmaceuticals Inc)|PPBT: P/S Multiple|Price to Sales American Oncology Network, Inc. (AONC)|Market Cap to Revenue BGNE|Price-to-Revenue Ratio CKPT|P/S Multiple ELEV|ICAD - Price to Sales|Price-to-Revenue Ratio Ikena Oncology IKNA|Market Capitalization-to-Revenue Ratio NTBL|VIRX: Market Cap to Revenue|MOR - P/S Multiple|NAYA (NAYA Biosciences Inc.) - Market Cap to Revenue|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio